Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of LY3981314 in Healthy Participants
NCT07005284Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of LY3981314 (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 25 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
LY3981314
Beyond the preview
Go deeper on NCT07005284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07005284.